12.1 Cancer Screening

12.1 Cancer Screening

Cancer screening is a cornerstone of clinical preventive medicine, enabling the detection of premalignant lesions or early-stage malignancies in asymptomatic individuals, which significantly reduces morbidity and mortality. In the United Arab Emirates, cancer screening guidelines are established by the Ministry of Health and Prevention (MOHAP) and the Dubai Health Authority (DHA) to address both global standards and regional epidemiological characteristics.

Breast Cancer Screening Guidelines

Breast cancer is the most common malignancy among women in the UAE. Early detection through screening mammography is the primary method for reducing mortality.

Average-Risk Guidelines and Modality

• UAE MOHAP/DHA Recommendation: Screening with biennial digital mammography (every 2 years) is recommended for average-risk women starting at age 40 and continuing to age 69.
• USPSTF Recommendation: In contrast, the United States Preventive Services Task Force (2024 update) recommends biennial screening mammography for women aged 40 to 74 years.
• Clinical Breast Exam (CBE): Local UAE guidelines recommend annual clinical breast exams for women aged 40 and older, whereas the USPSTF finds the evidence insufficient to assess the benefits and harms of CBE.

High-Risk Patient Surveillance

Women with risk factors that place them in a high-risk category (defined as a calculated lifetime breast cancer risk of >= 20% using tools like the Gail or Tyrer-Cuzick models, known carrier of BRCA1 or BRCA2 mutations, or a history of chest radiation therapy between ages 10 and 30) do not follow average-risk guidelines.

• Screening Modality: Annual screening mammography combined with annual breast Magnetic Resonance Imaging (MRI), typically staggered by 6 months.
• Starting Age: Screening should begin at age 30 (or 10 years earlier than the diagnosis age of the youngest first-degree relative, but not before age 25).

---

Cervical Cancer Screening Guidelines

Cervical cancer is highly preventable due to its long premalignant phase (cervical intraepithelial neoplasia, or CIN) and the availability of effective screening modalities targeting high-risk Human Papillomavirus (hrHPV).

Screening Cohorts and Intervals in the UAE

The UAE national guidelines recommend initiating screening at age 25 for sexually active females, reflecting regional vaccination and epidemiological patterns. This is a high-yield exam point, as the USPSTF recommends initiating screening at age 21.

Screening intervals are stratified by age cohorts:

1. Ages 25 to 29 Years:
   • Recommendation: Liquid-based cytology (Pap smear) alone every 3 years.
   • Rationale: Primary HPV screening is not recommended under age 30 because transient HPV infections are highly prevalent in this age group and typically resolve spontaneously. Universal HPV screening would lead to excessive, unnecessary colposcopies.
2. Ages 30 to 65 Years:
   • Preferred Option: Co-testing (cervical cytology plus high-risk HPV DNA testing) every 5 years.
   • Alternative Options: Primary HPV testing alone every 5 years, OR cervical cytology alone every 3 years.
3. Age > 65 Years:
   • Screening may be discontinued if the patient has had adequate negative prior screening and is not otherwise at high risk. Adequate negative screening is defined as:
     • 3 consecutive negative Pap smears within the past 10 years, or
     • 2 consecutive negative co-tests within the past 10 years, with the most recent test performed within 5 years.
   • Exception: Women with a history of high-grade lesions (CIN 2 or 3) or cervical cancer must continue screening for at least 20 years after regression or treatment, even if they pass age 65.

High-Risk Cohorts

More frequent screening is indicated for women with compromised immune systems (e.g., HIV-positive individuals, organ transplant recipients) or those with in-utero exposure to diethylstilbestrol (DES).

---

Colorectal Cancer (CRC) Screening Guidelines

Colorectal cancer is a major cause of cancer-related death. Early screening allows for the detection and removal of adenomatous polyps before they undergo malignant transformation.

Average-Risk Age Cohorts

Because colorectal cancer presents at a younger median age in the Middle East, the UAE guidelines mandate starting screening for average-risk individuals at age 40, continuing to age 75. In contrast, the USPSTF and American Cancer Society recommend starting at age 45.

Screening Modalities and Intervals

• Fecal Immunochemical Test (FIT): Performed annually. FIT specifically detects human globin and is preferred over guaiac-based fecal occult blood tests (gFOBT) as it does not require dietary restrictions. Any positive FIT must be followed by a diagnostic colonoscopy.
• Colonoscopy: Considered the gold standard, performed every 10 years for average-risk individuals. It serves both diagnostic and therapeutic (polypectomy) functions.
• Flexible Sigmoidoscopy: Performed every 5 years (or every 10 years if combined with annual FIT).

High-Risk Cohorts and Surveillance

• First-Degree Relative with CRC or Advanced Adenoma: For patients with a first-degree relative diagnosed with CRC or an advanced adenoma at age < 60, or two first-degree relatives diagnosed at any age:
  • Starting Age: Start colonoscopy screening at age 40, or 10 years earlier than the youngest affected relative's diagnosis, whichever comes first.
  • Interval: Repeat colonoscopy every 5 years.
• Lynch Syndrome (HNPCC): Annual colonoscopy starting at age 20 to 25.
• Familial Adenomatous Polyposis (FAP): Annual flexible sigmoidoscopy starting at age 10 to 12.